clinical trial · NCT07486895
Trial to Demonstrate the Equivalence of Two Different Strengths of Oral Centanafadine Capsules in Healthy Subjects
Otsuka Pharmaceutical Development & Commercialization, Inc.·phase1·completed·n = 44
Healthy Adult ParticipantsCentanafadine
brief summary
The purpose of this study is to demonstrate dose strength equivalence of 2 × 164.4 milligrams (mg) centanafadine (CTN) once daily (QD) extended-release (XR) capsules to a 1 × 328.8 mg centanafadine QD XR capsule in healthy adult participants.
started
Mar 8, 2023
primary completion
May 18, 2023
completion
May 18, 2023
last updated
Mar 23, 2026
official title
An Open-label, Randomized, Crossover Trial in Healthy Subjects to Assess Dose Strength Equivalence Among 164.4 and 328.8 mg Strengths of Oral Centanafadine QD XR Capsules
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol